A single dose of zoledronic acid (Reclast) given after 15 months of combination therapy with teriparatide (Forteo) and denosumab (Prolia) largely maintained the bone mineral…
A single dose of zoledronic acid (Reclast) given after 15 months of combination therapy with teriparatide (Forteo) and denosumab (Prolia) largely maintained the bone mineral…